Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| L2-483 | Other Identifier | Comitato Etico Territoriale Lombardia 2 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Individuals fulfilling the 2015 Chompret criteria. | ||
| Group 2 | Individuals fulfilling the Li-Fraumeni-Like (LFL) criteria according to Birch or Eeles. | ||
| Group 3 | Individuals undergoing Multi-Gene Transcriptional Profiling in the absence of Li-Fraumeni Sindrome/Li-Fraumeni-Like criteria. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall detection rate of Pathological Variants (PVs) in the TP53 gene. | To determine the overall detection rate of PVs in the TP53 gene among individuals referred to the Division of Cancer Prevention and Genetics at the IEO for TP53 genetic testing. Detection rate calculated as the number of patients with mutation of the TP53 gene divided by the total numer of patients tested. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Detection rate of pathological variants in the TP53 gene across cohort | Fisher's exact test or Chi-squared test will be applied, as appropriate, to compare the detection rate of pathological variants in the TP53 gene between different groups. | Baseline |
| Detection rate of Variant of Uncertain Significance in the TP53 gene. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO.
Participants will be stratified according to the referral criteria for genetic counseling and testing or the approach used.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mariarosaria Calvello, MD | Contact | +39 0294372651 | mariarosaria.calvello@ieo.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istituto Europeo di Oncologia | Recruiting | Milan | 20141 | Italy |
Not provided
Not provided
Not provided
Not provided
To determine the detection rate of Variant of Uncertain Significance (VUS) in the TP53 gene among all groups. Detection rate calculated as the number of patients with Variant of Uncertain Significance of the TP53 gene divided by the total numer of patients tested. Evaluation for potential reclassification of the detected TP53 VUS according to the 2025 ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Guidelines (v2.3.0) |
| Baseline |
| Detection rate of pathological variants and variants of Uncertain Significance in other cancer susceptibility genes. | Detection rate calculated as the number of patients with a mutation of gene other than the TP53 gene divided by the total numer of patients tested. | Baseline |
| Disease Free Survival | To compare the Disease Free Survival l of breast cancer patients carrying pathological variants in the TP53 gene with those observed in breast cancer patients tested through Multigene Panel Testing and who did not carry pathological variants or Variants of Uncertain Significance in any of the tested genes. Disease Free Survival will be defined as the time from surgery to invasive loco-regional recurrence, metastasis, other primary non-breast carcinomas, or death from any cause, whichever occurs first. | 5 years |
| Overall Survival (OS) | To compare the Overall Survival of breast cancer patients carrying pathological variants in the TP53 gene with those observed in breast cancer patients tested through Multigene Panel Testing and who did not carry pathological variants or Variants of Uncertain Significance in any of the tested genes. OS will be defined as the time from surgery to death from any cause. | 5 years |